M&A: Page 6
-
Cooper scraps $875M takeover of Cook Medical business after FTC investigation
The FTC said ending the planned acquisition “ensures that critical reproductive health markets remain competitive.”
By Nick Paul Taylor • Aug. 2, 2023 -
Baxter progresses with planned kidney care spinoff, expects biopharma solutions sale this quarter
The company expects hospital spending to increase in the second half of the year amid rising procedure volumes and a stabilizing supply chain.
By Elise Reuter • July 27, 2023 -
Teleflex to expand urology portfolio with $600M acquisition
The company reached an agreement to buy Palette Life Sciences, as it looks to grow through acquisitions.
By Elise Reuter • July 26, 2023 -
Big Health buys Limbix to add adolescent depression app to digital therapeutic portfolio
The phone-based treatment, SparkRx, uses self-guided, cognitive behavioral therapy to teach skills such as mood tracking.
By Nick Paul Taylor • July 18, 2023 -
Illumina hit by EU with maximum €432M fine for Grail acquisition
The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.
By Susan Kelly • July 12, 2023 -
Coloplast to pay $1.2B upfront to buy fish skin wound care business Kerecis
Kerecis’ fish skin biologic, which aids tissue regeneration, helped drive the company’s sales to $74.5 million last year.
By Nick Paul Taylor • July 10, 2023 -
ResMed buys Somnoware to expand sleep management software portfolio
The maker of sleep and respiratory care devices said it plans to retain all of Somnoware’s staff and maintain its open platform for patient testing and treatment.
By Nick Paul Taylor • July 7, 2023 -
Bausch + Lomb bulks up OTC business with J&J deal
The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.
By Ned Pagliarulo • July 6, 2023 -
Thermo Fisher to buy real-world evidence company CorEvitas for $913M
The acquisition is expected to complement Thermo Fisher’s clinical research business and become “immediately accretive” to its adjusted earnings per share.
By Elise Reuter • July 6, 2023 -
FTC proposes updates to merger review that could slow healthcare dealmaking
A new rule proposed by antitrust regulators would ask companies to provide additional information about planned mergers to help the Federal Trade Commission keep pace with increased deal volume and complexity.
By Emily Olsen • June 28, 2023 -
Restor3d inks Conformis buyout, adding hip and knee implants to portfolio
Restor3d, which makes 3D-printed devices for spine, ankle and upper extremity procedures, is buying Conformis at a 96% premium.
By Nick Paul Taylor • June 27, 2023 -
BD plans $540M sale of surgical instrumentation platform to Steris
The divestiture is part of BD’s strategy to simplify its portfolio and focus on higher-growth markets.
By Peter Green • Updated June 20, 2023 -
Glass Lewis, joining ISS, supports activist’s candidates for Masimo board
Saying it has “rarely” seen a circumstance where the “need for direct representation of a large shareholder in the boardroom was so apparent,” the proxy advisory firm backed Politan Capital’s bid for two board seats.
By Susan Kelly • June 16, 2023 -
As Illumina’s deSouza departs, will Grail go next?
The CEO’s resignation could signal a change of direction, as anti-trust regulators order Illumina to divest the liquid biopsy unit.
By Susan Kelly • June 12, 2023 -
Merit Medical buys two dialysis catheter lines for $132.5M combined
The acquisitions are expected to boost the Utah-based device maker’s annual revenue by about $30 million.
By Susan Kelly • June 9, 2023 -
SunMed agrees to $110M takeover of Avanos’ respiratory health unit, continuing M&A spree
Avanos, whose competitors include Stryker and Medline Industries, is selling the unit to narrow its focus on areas where it can succeed.
By Nick Paul Taylor • June 9, 2023 -
Novo Nordisk says in talks to acquire French device-maker Biocorp for $165M
The offer per share is about 20% more than Biocorp’s closing stock price on June 2. The two companies plan to focus on drug delivery solutions for chronic diseases, such as diabetes.
By Elise Reuter • Updated June 6, 2023 -
Getinge will acquire High Purity for as much as $370M to bolster biopharma business
The acquisition is aimed at strengthening Getinge’s position in the fast-growing area of custom single-use solutions for bioprocessing applications.
By Peter Green • May 31, 2023 -
Titan licenses robotic surgery intellectual property to Intuitive after failing to find buyer
After failing to bring its surgical robot to market and getting kicked off the Nasdaq, Titan is now marketing its intellectual property.
By Nick Paul Taylor • May 30, 2023 -
Illumina accused of ‘playing delay tactics’ to push back EU decision on divesting Grail: Financial Times
Delaying the decision to divest Grail could let Illumina sell the liquid biopsy business when the market is more favorable.
By Nick Paul Taylor • May 30, 2023 -
Boston Scientific cancels $230M stent deal after regulators erect barriers to acquisition
The Federal Trade Commission said Boston Scientific took the action in response to investigations by its staff and overseas enforcement partners.
By Nick Paul Taylor • May 26, 2023 -
Illumina chair loses to Icahn pick as proxy battle ends
The decision to replace board Chair John Thompson could change the company’s course as it decides whether to divest liquid biopsy company Grail.
By Elise Reuter • Updated May 25, 2023 -
Medtronic posts profit, sales growth in Q4, agrees to buy Korean diabetes patch maker
The company is “confident in delivering durable revenue growth in the year ahead” amid continued improvements in procedure volumes.
By Peter Green • May 25, 2023 -
Medtronic agrees to buy Korean insulin patch pump maker for $738m to boost diabetes business
The tubeless, disposable insulin patch made by EOFlow will be integrated into Medtronic’s MiniMed 780G system.
By Elise Reuter • May 25, 2023 -
A Boston Scientific purchase of Shockwave could be transformative — but at what price?
Boston Scientific has used “tuck-in” acquisitions to boost growth in the past. Some analysts say it should stay the course amid a report the company may make a bid.
By Susan Kelly • May 19, 2023